Linagliptin/metformin - GC Biopharma
Alternative Names: GC-2129ALatest Information Update: 26 Jun 2023
Price :
$50 *
At a glance
- Originator GC Biopharma
- Class Alkynes; Antihyperglycaemics; Biguanides; Insulin sensitisers; Piperidines; Purines; Quinazolines; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Diabetes mellitus
Most Recent Events
- 26 Jun 2023 Chemical structure information added
- 06 Feb 2023 GC Biopharma initiates Phase I trials in healthy volunteers in South Korea (PO) (NCT05729386)
- 03 Feb 2023 Phase-I clinical trials in Diabetes mellitus (In adults, In the elderly) in South Korea (PO, Tablet) (NCT05703984)